Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.24 USD
−93.61 M USD
0.00 USD
87.36 M
About Immunic, Inc.
Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis. The firm’s products include IMU-838, IMU-935, and IMU-856. The company is headquartered in New York, NY.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of IMUX is 1.18 USD — it has increased by 7.27% in the past 24 hours. Watch Immunic, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Immunic, Inc. stocks are traded under the ticker IMUX.
IMUX stock has risen by 11.32% compared to the previous week, the month change is a −17.48% fall, over the last year Immunic, Inc. has showed a 13.46% increase.
We've gathered analysts' opinions on Immunic, Inc. future price: according to them, IMUX price has a max estimate of 28.00 USD and a min estimate of 5.00 USD. Watch IMUX chart and read a more detailed Immunic, Inc. stock forecast: see what analysts think of Immunic, Inc. and suggest that you do with its stocks.
IMUX reached its all-time high on Jun 13, 2014 with the price of 1,408.00 USD, and its all-time low was 0.95 USD and was reached on Nov 13, 2023. View more price dynamics on IMUX chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
IMUX stock is 17.11% volatile and has beta coefficient of 2.16. Track Immunic, Inc. stock price on the chart and check out the list of the most volatile stocks — is Immunic, Inc. there?
Today Immunic, Inc. has the market capitalization of 106.29 M, it has increased by 4.72% over the last week.
Yes, you can track Immunic, Inc. financials in yearly and quarterly reports right on TradingView.
Immunic, Inc. is going to release the next earnings report on Feb 20, 2025. Keep track of upcoming events with our Earnings Calendar.
IMUX earnings for the last quarter are −0.24 USD per share, whereas the estimation was −0.22 USD resulting in a −9.89% surprise. The estimated earnings for the next quarter are −0.24 USD per share. See more details about Immunic, Inc. earnings.
Immunic, Inc. revenue for the last quarter amounts to 0.00 USD, despite the estimated figure of 6.00 K USD. In the next quarter, revenue is expected to reach 0.00 USD.
IMUX net income for the last quarter is −24.37 M USD, while the quarter before that showed −21.38 M USD of net income which accounts for −13.98% change. Track more Immunic, Inc. financial stats to get the full picture.
No, IMUX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 26, 2024, the company has 77.00 employees. See our rating of the largest employees — is Immunic, Inc. on this list?
Like other stocks, IMUX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Immunic, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Immunic, Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Immunic, Inc. stock shows the sell signal. See more of Immunic, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.